التجارب السريرية بالأسفل التجارب السريرية الحالية.45 دراسات في أمراض الكُلى وارتفاع ضغط الدم (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. TruGraf® Long-term Clinical Outcomes Study Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate post-transplant clinical outcomes in receipients of kidney transplants who are undergoing TruGraf® and TRAC™ monitoring. Monogenic Kidney Stone - Genetic Testing Rochester, Minn. 90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff. Evaluating Kidney Stones To Determine If They Lead to Kidney Disease Rochester, Minn. We hypothesize that clinical studies to investigate the role of individual proteins in kidney stone pathogenesis have likely been confounded by an unknown variety of underlying renal pathologies. Therefore, we propose to examine urinary protein crystallization inhibitors in patient populations that have been carefully phenotyped relative to renal stone precursor lesions by direct endoscopic visualization. In collaboration with Project #1, our second major goal is to use these accurately phenotyped patients in order to adapt modern dual-energy CT technology to develop a reliable noninvasive technique to accurately and noninvasively determine stone composition and visualize the earliest kidney stone precursor lesions. Our long-term goal is to improve CT technology so that it can be used to allow large-scale clinical protocols of accurately phenotyped, hence, homogeneous, patient populations. In a subset we will sample sterile stone, dental plaque, blood and urine samples for detailed microbiome analysis in order to determine the contribution of micro organisms to stone pathogensis. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients Rochester, Minn. The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension). التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 بالأسفل التجارب السريرية الحالية.45 دراسات في أمراض الكُلى وارتفاع ضغط الدم (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. TruGraf® Long-term Clinical Outcomes Study Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate post-transplant clinical outcomes in receipients of kidney transplants who are undergoing TruGraf® and TRAC™ monitoring. Monogenic Kidney Stone - Genetic Testing Rochester, Minn. 90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff. Evaluating Kidney Stones To Determine If They Lead to Kidney Disease Rochester, Minn. We hypothesize that clinical studies to investigate the role of individual proteins in kidney stone pathogenesis have likely been confounded by an unknown variety of underlying renal pathologies. Therefore, we propose to examine urinary protein crystallization inhibitors in patient populations that have been carefully phenotyped relative to renal stone precursor lesions by direct endoscopic visualization. In collaboration with Project #1, our second major goal is to use these accurately phenotyped patients in order to adapt modern dual-energy CT technology to develop a reliable noninvasive technique to accurately and noninvasively determine stone composition and visualize the earliest kidney stone precursor lesions. Our long-term goal is to improve CT technology so that it can be used to allow large-scale clinical protocols of accurately phenotyped, hence, homogeneous, patient populations. In a subset we will sample sterile stone, dental plaque, blood and urine samples for detailed microbiome analysis in order to determine the contribution of micro organisms to stone pathogensis. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients Rochester, Minn. The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE. Baxdrostat in Uncontrolled Hypertension on Two or More Medications Including Resistant Hypertension Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension). التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 طلب تحديد موعد الخبرة و مراتب التصنيفالأبحاث 19/06/2024 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة أمراض الكُلى وارتفاع ضغط الدمالأجزاءاطلب تحديد موعدنظرة عامةالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءمجموعات التخصصالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثالتكاليف والتأمين الصحيالأخبار من Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأجزاءاطلب تحديد موعدنظرة عامةالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءمجموعات التخصصالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثالتكاليف والتأمين الصحيالأخبار من Mayo Clinicإحالة المرضى ORG-20464466 الأقسام والمراكز الطبية أمراض الكُلى وارتفاع ضغط الدم